Kelly Covello

Kelly Covello

Company: Mirati Therapeutics

Job title: Head of Medical Affairs


Targeting KRAS Mutant Non Small Cell Lung Cancer with Adagrasib: Current Status and Future Questions 3:50 pm

History of targeting KRAS in the clinic and recent advancements to directly target KRAS G12C Clinical progress of KRAS G12C inhibitors (e.g. adagrasib) and treatment of patients with NSCLC Future questions and directions for targeting KRAS G12C, including biomarkers and combination strategiesRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.